Highlights

  • Artrya (ASX:AYA) signed a five-year contract with Huntsville Hospital Health System.
  • The agreement made Huntsville the first SAPPHIRE participant to become a commercial customer.
  • The Salix platform supports analysis and reporting of coronary CT imaging.
  • US rollout requires integration, Training and consistent clinical usage.

Artrya Limited develops cloud-based artificial intelligence software for analysing coronary computed tomography angiography and supporting clinical assessment of coronary artery disease. Artrya (ASX:AYA) shares finished at AUD 2.70 on November 18, 2026, down 6.90% for the day. Its September-quarter report described a new US hospital agreement, growing use of Salix products and implementation work across customer healthcare systems.

Salix Software and Clinical Use

Artrya’s Salix software is designed to help clinicians work with coronary CT angiography images, including anatomy and plaque-related assessment. The company is commercialising these services through US healthcare organisations while pursuing wider product availability. Its offering includes distinct modules with different intended uses and regulatory positions. Software deployment in a hospital requires more than a signed sales contract: information-technology connections, reporting workflows, clinical training, billing arrangements and clinician adoption all matter. Neither the availability of a module nor a customer contract independently establishes a particular utilisation rate.

Huntsville Commercial Agreement

In October 2026, the company announced a five-year commercial agreement with Huntsville Hospital Health System, which it described as its largest customer at that stage. Huntsville also became the first participant from Artrya’s SAPPHIRE study to move into full commercial use. The minimum contracted value was reported as US$0.5 million over five years. The system agreed to use Salix Coronary Anatomy on a subscription basis, with additional scan-based fees for certain modules subject to applicable clearance and use. The agreement sets a contractual floor, not a guaranteed projection of all potential scan revenue. Network-wide implementation and actual usage remain operational milestones.

September Quarter Operations

Artrya’s October 26 quarterly activities report discussed customer developments and the technical work required for deployment. It said Tanner Health had increased processing of coronary CT angiography examinations through Salix Coronary Anatomy after workflow changes. The company also pointed to activity around Salix Coronary Plaque use and pre-authorisation processes. These disclosures describe specific customer behaviour, not market-wide adoption. Artrya strengthened its board and executive Leadership during the period. Together, these elements show a commercial organisation moving from product introduction towards usage-based service delivery, where reported customer numbers and the Volume of reimbursable studies will be different performance measures.

Commercial and Clinical Constraints

Hospital procurement cycles, clinical validation, payer reimbursement, Cybersecurity requirements and system integration can affect the pace of software deployment. A contracted health system may adopt different modules at different times, and clinical staff must incorporate them into established radiology and cardiology processes. US regulatory clearance applies to specified products and indications rather than every proposed feature in the pipeline. These are relevant constraints without attributing the November share-price change to older announcements.

Monitoring Points and Key Insights

Artrya (ASX:AYA) can be assessed through disclosed installations, patient-scan volumes, product approvals and customer conversion rather than through contract headlines alone. The Huntsville agreement provides a defined commercial relationship, while Tanner’s utilisation update illustrates the importance of day-to-day workflow. Future quarterly reports may provide more detail on cash expenditure and Revenue recognition as deployments progress. Artrya (ASX:AYA) remains engaged in an early commercial scaling phase in which implementation timing and actual clinical activity are central to its operating results. The five-year agreement and the wider US rollout should not be interpreted as guaranteed earnings.